Gain of 1q as a prognostic biomarker in Wilms Tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: A SIOP renal tumours biology consortium study

Journal of Clinical Oncology

Volumn 34, Issue 26, 2016, Pages 3195-3203

  Chagtai, Tasnim ^a   Zill, Christina ^d   Dainese, Linda ^g,h   Wegert, Jenny ^d   Savola, Suvi ^j   Popov, Sergey ^b   Mifsud, William ^a   Vujanić, Gordan ^c   Sebire, Neil ^a   Le Bouc, Yves ^g,h   Ambros, Peter F ^m   Kager, Leo ^m,n   O'Sullivan, Maureen J ^o   Blaise, Annick ^g   Bergeron, Christophe ⁱ   Mengelbier, Linda Holmquist ^p   Gisselsson, David ^p   Kool, Marcel ^e   Tytgat, Godelieve A M ^l   Van Den Heuvel Eibrink, Marry M ^l   Graf, Norbert ^f   Van Tinteren, Harm ^k   Coulomb, Aurore ^g,h   Gessler, Manfred ^d   Williams, Richard Dafydd ^a   Pritchard Jones, Kathy ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g SORBONNE UNIVERSITÉ   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j MRC Holland   (Netherlands)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l Department of Radiation Oncology   (Netherlands)

^m Children's Cancer Research Institute   (Australia)

ⁿ ST ANNA CHILDREN S HOSPITAL   (Austria)

^o OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^p LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53; WT1 PROTEIN; TUMOR MARKER;

AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CHILD; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EVENT FREE SURVIVAL; FBXW7 GENE; FEASIBILITY STUDY; FEMALE; GENE; GENE DOSAGE; GENE LOSS; GENETIC ASSOCIATION; HAZARD RATIO; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIVARIATE ANALYSIS; NEPHROBLASTOMA; ONCOGENE C MYB; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX; UNIVARIATE ANALYSIS; WTX GENE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CHROMOSOME 1; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; NEPHRECTOMY; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; WILMS TUMOR;

BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEPHRECTOMY; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WILMS TUMOR;

EID: 84989908986     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.0001     Document Type: Article

References (33)

1. Breslow N, Olshan A, Beckwith JB, et al: Epidemiology of Wilms tumor. Med Pediatr Oncol 21:172-181, 1993
2. Pritchard-Jones K, Moroz V, Vujanic G, et al: Treatment and outcome of Wilms' tumour patients: An analysis of all cases registered in the UKW3 trial. Ann Oncol 23:2457-2463, 2012
3. Kalapurakal JA, Dome JS, Perlman EJ, et al: Management of Wilms' tumour: Current practice and future goals. Lancet Oncol 5:37-46, 2004
4. Vujanić GM, Sandstedt B, Harms D, et al: Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38:79-82, 2002
5. Pritchard-Jones K, Bergeron C, de Camargo B, et al: Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial. Lancet 386:1156-1164, 2015
6. van den Heuvel-Eibrink MM, van Tinteren H, Bergeron C, et al: Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). Eur J Cancer 51:498-506, 2015
7. Bonetta L, Kuehn SE, Huang A, et al: Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science 250:994-997, 1990
8. Call KM, Glaser T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990
9. Gessler M, Poustka A, Cavenee W, et al: Homozygous deletion in Wilms tumours of a zincfinger gene identified by chromosome jumping. Nature 343:774-778, 1990
10. Koesters R, Ridder R, Kopp-Schneider A, et al: Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59:3880-3882, 1999
11. Rivera MN, Kim WJ, Wells J, et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315:642-645, 2007
12. Bardeesy N, Falkoff D, Petruzzi MJ, et al: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91-97, 1994
13. Williams RD, Al-Saadi R, Chagtai T, et al: Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16:2036-2045, 2010
14. Rakheja D, Chen KS, Liu Y, et al: Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802, 2014
15. Torrezan GT, Ferreira EN, Nakahata AM, et al: Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun 5:4039, 2014
16. Walz AL, Ooms A, Gadd S, et al: Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286-297, 2015
17. Erratum Walz AL, Ooms A, Gadd S, et al: Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:426, 2015
18. Wegert J, Ishaque N, Vardapour R, et al: Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27:298-311, 2015
19. Williams RD, Chagtai T, Alcaide-German M, et al: Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 6:7232-7243, 2015
20. Scott RH, Douglas J, Baskcomb L, et al: Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 40:1329-1334, 2008
21. Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312-7321, 2005
22. Maschietto M, Williams RD, Chagtai T, et al: TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One 9:e109924, 2014
23. Hing S, Lu YJ, Summersgill B, et al: Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 158:393-398, 2001
24. Lu YJ, Hing S, Williams R, et al: Chromosome 1q expression profilingand relapse in Wilms' tumour. Lancet 360:385-386, 2002
25. Natrajan R, Williams RD, Hing SN, et al: Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 210:49-58, 2006
26. Perotti D, Spreafico F, Torri F, et al: Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes Chromosomes Cancer 51:644-653, 2012
27. Gratias EJ, Jennings LJ, Anderson JR, et al: Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. Cancer 119:3887-3894, 2013
28. Segers H, van den Heuvel-Eibrink MM, Williams RD, et al: Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes Chromosomes Cancer 52:1065-1074, 2013
29. Schouten JP, McElgunn CJ, Waaijer R, et al: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57, 2002
30. Furtwängler R, Pritchard-Jones K: Treatment of Wilms tumour: The SIOP approach, in Pritchard-Jones K, Dome JS (eds): Renal Tumours of Childhood: Biology and Therapy. Berlin Heidelberg, Germany, Springer-Verlag, 2014, pp 101-118
31. Williams RD, Al-Saadi R, Natrajan R, et al: Molecular profilingreveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 50:982-995, 2011
32. Hill DA, Shear TD, Liu T, et al: Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 97:2318-2326, 2003
33. Graf N, van Tinteren H, Pritchard-Jones K, et al: Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? Pediatr Blood Cancer 57:741-742, 2011